These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 28939847)
1. Dual "mAb" HER family blockade in head and neck cancer human cell lines combined with photon therapy. Guy JB; Méry B; Ollier E; Espenel S; Vallard A; Wozny AS; Simonet S; Lauret A; Battiston-Montagne P; Ardail D; Alphonse G; Rancoule C; Rodriguez-Lafrasse C; Magné N Sci Rep; 2017 Sep; 7(1):12207. PubMed ID: 28939847 [TBL] [Abstract][Full Text] [Related]
2. Carbon ion irradiation withstands cancer stem cells' migration/invasion process in Head and Neck Squamous Cell Carcinoma (HNSCC). Moncharmont C; Guy JB; Wozny AS; Gilormini M; Battiston-Montagne P; Ardail D; Beuve M; Alphonse G; Simoëns X; Rancoule C; Rodriguez-Lafrasse C; Magné N Oncotarget; 2016 Jul; 7(30):47738-47749. PubMed ID: 27374096 [TBL] [Abstract][Full Text] [Related]
3. Combining radiation to EGFR and Bcl-2 blockade: a new approach to target cancer stem cells in head and neck squamous cell carcinoma. Guy JB; Espenel S; Louati S; Gauthier A; Garcia MA; Vial N; Malésys C; Ardail D; Alphonse G; Wozny AS; Rodriguez-Lafrasse C; Magné N J Cancer Res Clin Oncol; 2021 Jul; 147(7):1905-1916. PubMed ID: 33791846 [TBL] [Abstract][Full Text] [Related]
4. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models. Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485 [TBL] [Abstract][Full Text] [Related]
5. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584 [TBL] [Abstract][Full Text] [Related]
6. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208 [TBL] [Abstract][Full Text] [Related]
7. Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies. Pollock NI; Wang L; Wallweber G; Gooding WE; Huang W; Chenna A; Winslow J; Sen M; DeGrave KA; Li H; Zeng Y; Grandis JR Clin Cancer Res; 2015 Oct; 21(20):4597-606. PubMed ID: 26138066 [TBL] [Abstract][Full Text] [Related]
8. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma. Jiang N; Wang D; Hu Z; Shin HJ; Qian G; Rahman MA; Zhang H; Amin AR; Nannapaneni S; Wang X; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Ma J; Chen ZG; Saba NF Mol Cancer Ther; 2014 Jul; 13(7):1826-36. PubMed ID: 24748655 [TBL] [Abstract][Full Text] [Related]
9. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Iida M; Bahrar H; Brand TM; Pearson HE; Coan JP; Orbuch RA; Flanigan BG; Swick AD; Prabakaran PJ; Lantto J; Horak ID; Kragh M; Salgia R; Kimple RJ; Wheeler DL Mol Cancer Ther; 2016 Sep; 15(9):2175-86. PubMed ID: 27422810 [TBL] [Abstract][Full Text] [Related]
10. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. Zhang L; Castanaro C; Luan B; Yang K; Fan L; Fairhurst JL; Rafique A; Potocky TB; Shan J; Delfino FJ; Shi E; Huang T; Martin JH; Chen G; Macdonald D; Rudge JS; Thurston G; Daly C Mol Cancer Ther; 2014 May; 13(5):1345-55. PubMed ID: 24634416 [TBL] [Abstract][Full Text] [Related]
11. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149 [TBL] [Abstract][Full Text] [Related]
12. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab. Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004 [TBL] [Abstract][Full Text] [Related]
13. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance. O'Keefe RA; Bhola NE; Lee DS; Johnson DE; Grandis JR PLoS One; 2020; 15(1):e0227261. PubMed ID: 31914141 [TBL] [Abstract][Full Text] [Related]
14. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711 [TBL] [Abstract][Full Text] [Related]
15. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma. Baro M; Lopez Sambrooks C; Burtness BA; Lemmon MA; Contessa JN Mol Cancer Ther; 2019 Nov; 18(11):2124-2134. PubMed ID: 31387891 [TBL] [Abstract][Full Text] [Related]
16. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. Wang Z; Martin D; Molinolo AA; Patel V; Iglesias-Bartolome R; Degese MS; Vitale-Cross L; Chen Q; Gutkind JS J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25099740 [TBL] [Abstract][Full Text] [Related]
17. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer. Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685 [TBL] [Abstract][Full Text] [Related]
18. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. D'Amato V; Rosa R; D'Amato C; Formisano L; Marciano R; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fusciello C; Veneziani BM; De Placido S; Bianco R Br J Cancer; 2014 Jun; 110(12):2887-95. PubMed ID: 24823695 [TBL] [Abstract][Full Text] [Related]
19. MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. Novoplansky O; Fury M; Prasad M; Yegodayev K; Zorea J; Cohen L; Pelossof R; Cohen L; Katabi N; Cecchi F; Joshua BZ; Popovtzer A; Baselga J; Scaltriti M; Elkabets M Int J Cancer; 2019 Aug; 145(3):748-762. PubMed ID: 30694565 [TBL] [Abstract][Full Text] [Related]
20. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer. Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]